MX367811B - D-metadona para el tratamiento de síntomas psiquiátricos. - Google Patents

D-metadona para el tratamiento de síntomas psiquiátricos.

Info

Publication number
MX367811B
MX367811B MX2015006720A MX2015006720A MX367811B MX 367811 B MX367811 B MX 367811B MX 2015006720 A MX2015006720 A MX 2015006720A MX 2015006720 A MX2015006720 A MX 2015006720A MX 367811 B MX367811 B MX 367811B
Authority
MX
Mexico
Prior art keywords
alpha
methadone
psychiatric symptoms
treatment
receptor
Prior art date
Application number
MX2015006720A
Other languages
English (en)
Other versions
MX2015006720A (es
Inventor
Paolo L Manfredi
Charles E Inturrisi
Original Assignee
Relmada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relmada Therapeutics Inc filed Critical Relmada Therapeutics Inc
Publication of MX2015006720A publication Critical patent/MX2015006720A/es
Publication of MX367811B publication Critical patent/MX367811B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un método de tratamiento de síntomas psiquiátricos en un sujeto que tiene un receptor de NMDA y un receptor de NE, que incluye administrar d-metadona, d-metadol, d-alfa-acetilmetadol, I-alfa-acetilmetadol, d-alfa-normetadol, I-alfa-normetadol, sales farmacéuticamente aceptables de la misma, o mezclas de la misma al sujeto, bajo condiciones efectivas para que la sustancia se una al receptor de NMDA y al receptor de NE del sujeto.
MX2015006720A 2012-09-27 2013-09-25 D-metadona para el tratamiento de síntomas psiquiátricos. MX367811B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706178P 2012-09-27 2012-09-27
US13/803,375 US9468611B2 (en) 2012-09-27 2013-03-14 d-Methadone for the treatment of psychiatric symptoms
PCT/US2013/061639 WO2014052427A1 (en) 2012-09-27 2013-09-25 D-methadone for the treatment of psychiatric symptoms

Publications (2)

Publication Number Publication Date
MX2015006720A MX2015006720A (es) 2016-06-28
MX367811B true MX367811B (es) 2019-09-06

Family

ID=50339472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006720A MX367811B (es) 2012-09-27 2013-09-25 D-metadona para el tratamiento de síntomas psiquiátricos.

Country Status (17)

Country Link
US (2) US9468611B2 (es)
EP (1) EP2906209B1 (es)
KR (2) KR20150085510A (es)
CN (1) CN105473135B (es)
AU (2) AU2013323645B2 (es)
CA (1) CA2893238C (es)
DK (1) DK2906209T3 (es)
ES (1) ES2686845T3 (es)
HK (1) HK1213797A1 (es)
HR (1) HRP20181481T1 (es)
HU (1) HUE039681T2 (es)
MX (1) MX367811B (es)
PL (1) PL2906209T3 (es)
PT (1) PT2906209T (es)
RS (1) RS57724B1 (es)
SI (1) SI2906209T1 (es)
WO (1) WO2014052427A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682049B2 (en) 2015-02-18 2017-06-20 Y. Eugene Mironer Non-racemic mixtures of various ratios of D- and L-methadone and methods of treating pain using the same
US10040752B2 (en) 2015-08-24 2018-08-07 Cody Laboratories, Inc. Synthesis of levomethadone hydrochloride or dextromethadone hydrochloride and methods for use thereof
AU2018215056A1 (en) * 2017-01-31 2019-08-08 Charles E. Inturrisi D-methadone and its derivatives for use in the treatment of disorders of the nervous system
EP3813807A1 (en) 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP4219445A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
US20230063459A1 (en) 2019-12-30 2023-03-02 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023509484A (ja) * 2020-01-03 2023-03-08 ユニバーシティ オブ パドヴァ 神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
ATE357226T1 (de) * 1997-01-22 2007-04-15 Cornell Res Foundation Inc (d)-methadon, ein nicht-opioides schmerzmittel
US20060167032A1 (en) * 2002-01-16 2006-07-27 Galer Bradley S Pharmaceutical composition and method for treating disorders of the central nervous system
US8202525B2 (en) * 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications

Also Published As

Publication number Publication date
EP2906209B1 (en) 2018-06-20
PL2906209T3 (pl) 2018-12-31
HRP20181481T1 (hr) 2018-11-02
ES2686845T3 (es) 2018-10-22
EP2906209A1 (en) 2015-08-19
AU2013323645A1 (en) 2015-05-14
CA2893238C (en) 2020-11-10
HUE039681T2 (hu) 2019-01-28
SI2906209T1 (sl) 2018-11-30
CN105473135B (zh) 2018-09-14
CN105473135A (zh) 2016-04-06
MX2015006720A (es) 2016-06-28
AU2017276189A1 (en) 2018-01-18
HK1213797A1 (zh) 2016-07-15
KR20180001581A (ko) 2018-01-04
KR101969667B1 (ko) 2019-04-17
CA2893238A1 (en) 2014-04-03
US20140088155A1 (en) 2014-03-27
RS57724B1 (sr) 2018-12-31
KR20150085510A (ko) 2015-07-23
US20160310450A1 (en) 2016-10-27
US9855226B2 (en) 2018-01-02
AU2013323645B2 (en) 2017-11-02
DK2906209T3 (en) 2018-10-01
US9468611B2 (en) 2016-10-18
PT2906209T (pt) 2018-10-16
AU2017276189B2 (en) 2018-12-06
WO2014052427A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
PH12015502075B1 (en) Treatment of cataplexy
WO2012062925A3 (en) Compounds and methods for treating pain
MY202135A (en) Uses of neuroactive compounds
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2012013740A (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
NZ722600A (en) Methods of treating mild brain injury
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
EA201690327A1 (ru) Терапевтические способы
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
PH12014502065A1 (en) Vesicular formulations
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2018001684A (es) Metodo de curacion de heridas.
MX360001B (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2013011623A (es) Regimenes de tratamiento.
MX2012014971A (es) Dosis fija de combinacion de sildenafilo y dapoxetina.
MX2013008137A (es) Procedimientos para tratar la prostatitis.

Legal Events

Date Code Title Description
FG Grant or registration